Evaluation of Prevalence and Clinical Impact of Atrial Fibrillation in Elderly Patients With Cryptogenic Stroke and High-Risk Patent Foramen Ovale

UnknownOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

October 2, 2019

Primary Completion Date

October 2, 2024

Study Completion Date

October 2, 2024

Conditions
Cryptogenic StrokeHigh Risk Patent Foramen Ovale
Interventions
PROCEDURE

Percutaneous device closure

If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.

Trial Locations (1)

Unknown

RECRUITING

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

Asan Medical Center

OTHER

NCT04285918 - Evaluation of Prevalence and Clinical Impact of Atrial Fibrillation in Elderly Patients With Cryptogenic Stroke and High-Risk Patent Foramen Ovale | Biotech Hunter | Biotech Hunter